Surviving Childhood Cancer Increase Risk of Heart Disease in Adulthood
Those who survive cancer as children are shown to be at greater risks of heart problems in early adulthood:
"Children and young people who survive cancer have a significantly higher risk of developing heart disease as young adults because of the cancer treatment they received, researchers said Wednesday.
A study by doctors from the United States found that young adult survivors of childhood cancer are at risk of a range of cardiac problems such as heart failure, heart attacks, or heart disease and the risks continued up to 30 years after treatment.
"Young adults who survive childhood or adolescent cancer are clearly at risk for early cardiac morbidity and mortality not typically recognized within this age group," said Daniel Mulrooney from the University of Minnesota, who led the study."
Read More: http://www.canada.com/life/diversions/games/badapple/Child+cancer+surviv...
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
